Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Palm Therapeutics is a next-generation therapeutics company to cure cancer at its source.
Fzata's novel platform modality for oral biologics is Bioengineered Probiotic Yeast Medicines (BioPYM) with over 10 GI drug candidates.
Neurexis Therapeutics develops therapeutic peptide for post-insult neuroprotection.
Pioneering innovative biomedical technologies
Opsin Biotherapeutics develops a pipeline of opsin-based gene therapies for pain management
UN&UP is an organization that helps people with unmet needs and those who are underprivileged.
Kannalife is a biopharmaceutical company that focuses on innovation in research and development of novel cannabinoid therapeutic agents.
PathMaker Neurosystems is a neurotechnology company that develops treatment for neuromotor disorders.
Neuroene Therapeutics offers novel small molecule mitochondrial therapeutics for epilepsy, Parkinson's Disease, and mitochondrial disease.
Quiver Bioscience develops medicines for brain disorders using human disease models and advanced AI technologies.
Evon Medics, LLC is focused on developing and delivering breakthrough therapeutics and devices to address brain-related conditions.
Cyprium Therapeutics focuses on the development of novel therapies treatment for Menkes disease and related copper metabolism disorders.
Sinopia Biosciences enables data-driven drug discovery by means of multi-omics data, machine learning, network analyses, and disease models.
Amydis is a pharmaceutical company that focuses on developing innovative chemistry to detect diseases.
Navega Therapeutics is a preclinical stage company developing epigenetic gene therapies for neurological and ophthalmic diseases.
Alume Biosciences is a biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use.
Neuro42 is developing and commercializing advanced MRI and robotics technology for diagnosis and image-guided interventions.
WideTrial is a third-party sponsor of group-level Expanded Access programs (EAPs).
2Morrow offers evidence-based digital health and DTx programs to some of the nation's largest employers, states and health plans.
Eikonizo Therapeutics is a biopharmaceutical company.
RevBio was started with one goal in mind—to end medicine’s 50-year search for a biocompatible bone adhesive.
National Institute of Neurological Disorders and Stroke has invested in 40 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
National Institute of Neurological Disorders and Stroke's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Medical Device. The firm invests across 22 different industry categories.
Among tracked funding rounds, WideTrial received $22.0M in a Grant round. National Institute of Neurological Disorders and Stroke's total known invested capital is $164.9M.
National Institute of Neurological Disorders and Stroke's average investment size is $4.2M across its portfolio of 40 companies.
Recent National Institute of Neurological Disorders and Stroke portfolio additions include Palm Therapeutics, Fzata, Inc., Neurexis Therapeutics, Great Lakes NeuroTechnologies Inc., Opsin Biotherapeutics. These companies were founded in 2020 or later.